Intensity Therapeutics, Inc.
$5.21
▲
0.19%
2026-04-21 07:33:00
www.intensitytherapeutics.com
NCM: INTS
Explore Intensity Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.46 M
Current Price
$5.21
52W High / Low
$50 / $4.63
Stock P/E
—
Book Value
$4.7
Dividend Yield
—
ROCE
-100.14%
ROE
-1.57%
Face Value
—
EPS
$-8.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
4.23
Debt / Equity
0.93
Current Ratio
5.92
Quick Ratio
5.92
Forward P/E
-1.38
Price / Sales
—
Enterprise Value
$2.16 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$48.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
| 2. | Celldex Therapeutics, Inc. | $34.38 | — | $2.7 B | — | -54.02% | -40.62% | $35.29 / $17.45 | $7.92 |
| 3. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 4. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 5. | Lipocine Inc. | $2.3 | — | $16.86 M | — | -71.64% | -54.28% | $12.37 / $1.81 | $2.35 |
| 6. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 7. | Cocrystal Pharma, Inc. | $1.51 | — | $20.82 M | — | -120.22% | -1.11% | $2.67 / $0.86 | $0.46 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.14 M | -2.73 M | -2.71 M | -3.39 M | -3.2 M | — |
| Net Profit | -3.05 M | -2.67 M | -2.54 M | -3.35 M | -3.18 M | — |
| EPS in Rs | -1.2 | -1.05 | -1 | -1.32 | -1.25 | -6.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -11.97 M | -16.59 M | -8.32 M | -7.55 M |
| Net Profit | -11.61 M | -16.27 M | -10.54 M | -7.58 M |
| EPS in Rs | -4.57 | -6.4 | -4.15 | -2.98 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.1 M | 4.78 M | 17.3 M | 1.76 M |
| Total Liabilities | 2.23 M | 1.86 M | 4.13 M | 16.86 M |
| Equity | 11.88 M | 2.92 M | 13.16 M | -15.1 M |
| Current Assets | 12.71 M | 3.36 M | 15.46 M | 1.45 M |
| Current Liabilities | 2.15 M | 1.75 M | 3.96 M | 6.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -9.23 M | -15.22 M | -7.21 M | -5.48 M |
| Investing CF | 0 M | 6.35 M | -6.02 M | 0 M |
| Financing CF | 18.56 M | 2.9 M | 20.47 M | 2.25 M |
| Free CF | -9.23 M | -15.22 M | -7.21 M | -5.48 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -54.37% | -38.99% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-02-19 | 1:0.04 |